Articles

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study

Amsterdam University Medical Centers, University of Amsterdam, The Netherlands;
Dept of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden;
Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece;
Hospital del Mar, Barcelona, Spain;
University Hospital Brno, Masaryk University, Brno, Czech Republic;
Dept of Clinical Genetics, Amsterdam University Medical Centers, Univ of Amsterdam, The Netherlands;
Dept of Clinical Genetics, Amsterdam University Medical Centers, Univ of Amsterdam, The Netherlands;
IBSAL, IBMCC, Centro de Investigación del Cancer, Universidad de Salamanca-CSIC, Spain;
Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;
Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;
Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;
Division of Clinical Genetics, Dept of Laboratory Medicine, Lund University, Lund, Sweden;
Cancer Genomics, Academic Unit of Cancer Sciences, University of Southampton, Southampton, UK;
Dept of Genetics, University Medical Center Groningen, University of Groningen, The Netherlands;
Dept of Genetics, University Medical Center Groningen, University of Groningen, The Netherlands;
Dept of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK;
Cytogenetics department, St Vincent Hospital Melbourne, Victoria, Australia;
Oncogenomic laboratory, Dept of Hematology, Lausanne University Hospital (CHUV), Switzerland;
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;
Department of Oncology-Pathology, Karolinska Institutet, Stockholm;
University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
Dept. of Experimental Oncology, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milan;
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, The Netherlands;
Laboratori de Citogenetica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain;
CEITEC, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
St Vincent Hospital Melbourne, Peter MacCallum Cancer Center, University of Melbourne, Australia;
Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France;
Service d'Hematologie Biologique, Hopital Pitié-Salpetriere, APHP, Paris, France;
Dept of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK;
MLL Munich Leukemia Laboratory, Munich, Germany;
Oncogenomic laboratory, Dept of Hematology, Lausanne University Hospital (CHUV), Switzerland;
Radboud University Medical Center, Dept of Human Genetics, Nijmegen, The Netherlands;
Amsterdam University Medical Centers, University of Amsterdam, The Netherlands;
Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece;
Dept of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;
Cancer Genomics, Academic Unit of Cancer Sciences, University of Southampton, UK;
Amsterdam University Medical Centers, University of Amsterdam, The Netherlands;
Hematology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands
Haematologica Early view Jan 23, 2020 https://doi.org/10.3324/haematol.2019.239947